These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 26855630

  • 1. Bisphosphonate Treatment in Osteoporosis: Optimal Duration of Therapy and the Incorporation of a Drug Holiday.
    Villa JC, Gianakos A, Lane JM.
    HSS J; 2016 Feb; 12(1):66-73. PubMed ID: 26855630
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA, Taisne N, Legroux I, Cortet B, Paccou J.
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [Abstract] [Full Text] [Related]

  • 6. Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea.
    Lee SH, Gong HS, Kim TH, Park SY, Shin JH, Cho SW, Byun DW.
    J Bone Metab; 2015 Nov; 22(4):167-74. PubMed ID: 26713307
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Osteoporosis: long-term treatment versus drug holiday-what is the evidence?].
    Farahmand P, Cassens J.
    Z Rheumatol; 2019 Dec; 78(10):904-909. PubMed ID: 31654138
    [Abstract] [Full Text] [Related]

  • 9. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
    Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Pérez-López FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Trémollieres FA, Goulis DG.
    Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study.
    Adams AL, Adams JL, Raebel MA, Tang BT, Kuntz JL, Vijayadeva V, McGlynn EA, Gozansky WS.
    J Bone Miner Res; 2018 Jul; 33(7):1252-1259. PubMed ID: 29529334
    [Abstract] [Full Text] [Related]

  • 11. Long-term use of bisphosphonates in osteoporosis.
    Watts NB, Diab DL.
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [Abstract] [Full Text] [Related]

  • 12. Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis.
    Murphy-Menezes M.
    Clin Ther; 2015 Jul 01; 37(7):1573-86. PubMed ID: 25913920
    [Abstract] [Full Text] [Related]

  • 13. Atypical femur fracture during bisphosphonate drug holiday: a case series.
    Lovy AJ, Koehler SM, Keswani A, Joseph D, Hasija R, Ghillani R.
    Osteoporos Int; 2015 Jun 01; 26(6):1755-8. PubMed ID: 25832177
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of fracture risk and potential drug holidays for postmenopausal women on long-term bisphosphonate therapy.
    Kostoff MD, Saseen JJ, Borgelt LM.
    Int J Womens Health; 2014 Jun 01; 6():423-8. PubMed ID: 24855392
    [Abstract] [Full Text] [Related]

  • 15. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S, Greenspan SL.
    Osteoporos Int; 2019 Apr 01; 30(4):705-720. PubMed ID: 30623214
    [Abstract] [Full Text] [Related]

  • 16. Risks and benefits of long-term bisphosphonate therapy.
    Schmidt GA, Horner KE, McDanel DL, Ross MB, Moores KG.
    Am J Health Syst Pharm; 2010 Jun 15; 67(12):994-1001. PubMed ID: 20516469
    [Abstract] [Full Text] [Related]

  • 17.
    Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC.
    ; 2018 06 15. PubMed ID: 30325616
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA, MacDonald R, Forte ML, Rosebush CE, Ensrud KE, Schousboe JT, Nelson VA, Ullman K, Butler M, Olson CM, Taylor BC, Brasure M, Wilt TJ.
    Ann Intern Med; 2019 Jul 02; 171(1):37-50. PubMed ID: 31009947
    [Abstract] [Full Text] [Related]

  • 19. Fracture Risk Following Discontinuation of Teriparatide: A Review of the Literature.
    Murphy PZ, Iranikhah M, Deas CM, Freeman MK.
    Consult Pharm; 2018 Jul 01; 33(7):365-375. PubMed ID: 29996965
    [Abstract] [Full Text] [Related]

  • 20. The use of bisphosphonates in women: when to use and when to stop.
    Gatti D, Adami S, Viapiana O, Rossini M.
    Expert Opin Pharmacother; 2015 Jul 01; 16(16):2409-21. PubMed ID: 26357942
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.